抗卵巢癌新药——聚腺苷二磷酸核糖聚合酶抑制剂niraparib 被引量：2

A new drug for treatment of ovarian cancer——PARP inhibitor niraparib

导出

摘要 niraparib为口服聚腺苷二磷酸核糖聚合酶抑制剂。2017年3月27日,美国食品和药物管理局批准niraparib用于对铂类完全或部分响应的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的成年患者的维持治疗。本文主要介绍其药物作用机制、药动学、疗效、安全性及临床研究进展。 Niraparib, an orally available poly （ADP-ribose） polymerase （PARP） inhibitor, has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum- based chemotherapy by U.S. Food and Drug Administration on March 27, 2017. This article reviewed the advances in mechanism of action, clinical pharmacology, clinical efficacy and safety of niraparib.

作者张亚安任莉萍潘喆周新月

机构地区东南大学成贤学院制药与化学工程学院

出处《中国新药与临床杂志》 CSCD 北大核心 2017年第9期511-514,共4页 Chinese Journal of New Drugs and Clinical Remedies

基金江苏省高等学校大学生实践创新训练计划项目(201612689021X)

关键词 niraparib 卵巢肿瘤腹膜肿瘤 PARP抑制剂 niraparib ovarian neoplasms peritoneal neoplasms PARP inhibitors

分类号 R737.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献2

1李崧,田红旗.卵巢癌分子靶向治疗研究进展[J].中国新药与临床杂志,2016,35(11):759-766. 被引量：7
2黄河,曹阳,吴英理,阎骅.PARP抑制剂联合化疗药物治疗恶性肿瘤的研究进展[J].肿瘤,2013,33(4):372-377. 被引量：13

二级参考文献30

1RISHNAKUMAR R, KRAUS W L. The PARP side of the lucleus: Molecular actions, physiological outcomes, and :linical targets[J]. Mol Cell, 20% 0, 39{1 ):8-24.
2D'AMOURS D, SALLMANN F R, DIXIT V M, eta/. Gain- of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: Implications for apoptosis[J].J Cell Sci, 2001, 114(Pt 20):3771-3778.
3BRYANT H E, SCHULTZ N, THOMAS H D, et al. Specific killing of BRAC2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase[J]. Nature, 2005, 434(7035):913-917.
4WlLLIAMSON C T, MUZIK H, TURHAN A G, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors[J]. Mol Cancer ?-her, 2010, 9(2):347-357.
5TENTORI L, MUZI A, DORIO A S, et al. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent[J]. Curt Cancer Drug Targets, 2010,10(4):368-383.
6HORTON T M, JENKINS G, PATI D, et al. Poly(AOP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia ceils: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity[J]. Mol Cancer Ther, 2009, 8(8):2232-2242.
7BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium[J]. Cancer Biol Ther, 2009, 8(1):2-3.
8KUMMAR S, JIJ, MORGAN R, et al. A phase ][ study of veliparib in combination with metronomiccyclophosphamide in adults with refractory solid tumors and lymphomas[J]. C/in Cancer Res, 201 2, 18(6):1726-1734.
9LOSER D A, SHIBATA A, SHIBATA A K, eta/. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair[J]. Mol Cancer Ther, 2010, 9(6):1 775-1 787.
10Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant[J]. Oncology (Williston Park), 2011,25(12):1213, 1232.